CatalystFDA/Bio

Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer

FDA Breakthrough Therapy Designation for daraxonrasib plus chemotherapy in first-line metastatic pancreatic cancer.

What changed

FDA Breakthrough Therapy Designation for daraxonrasib plus chemotherapy in first-line metastatic pancreatic cancer.

Why it matters

FDA Breakthrough Therapy Designation for daraxonrasib plus chemotherapy in first-line metastatic pancreatic cancer. — impact context not separately stored; see What changed.

Sources

eodhd